Yongin City Approves 34,128-Square-Meter Complex in Moksin-ri, Wonsam-myeon
Construction to Begin at Year-End; Completion Expected in December 2029
Hanlim Pharmaceutical Subsidiary to Expand Production Lines for Active Pharmaceutical Ingredients and Novel Drugs

A new industrial complex for the production of active pharmaceutical ingredients and the development of novel biopharmaceuticals will be built in Wonsam-myeon, Cheoin-gu, Yongin Special City, Gyeonggi Province. Key biotech infrastructure is also steadily joining the area around Cheoin-gu, which has emerged as a semiconductor hub.

Artist's rendering of the HL Genomics General Industrial Complex. Provided by Yongin City.

Artist's rendering of the HL Genomics General Industrial Complex. Provided by Yongin City.

View original image

Yongin City Mayor Lee Sangil announced on Nov. 2 that it had approved plans for the Yongin HL Genomics General Industrial Complex, to be built in the area around 408-20 Moksin-ri, Wonsam-myeon.


The complex will be developed by HL Genomics, a subsidiary of Hanlim Pharmaceutical, with an investment of KRW 27.5 billion. The total site covers 34,128 square meters, or about 10,300 pyeong. HL Genomics, the project operator and a subsidiary of Hanlim Pharmaceutical, is pursuing the project to expand facilities for manufacturing the active pharmaceutical ingredients needed to produce Hanlim Pharmaceutical's medicines. Construction is scheduled to begin by the end of 2026, with completion expected in December 2029.


Factories and research facilities will occupy 26,147 square meters, or 76.6% of the total site. The project will also improve 1,512 square meters of roads to provide access to and from the complex.


HL Genomics plans to expand its production facilities in conjunction with its existing factory. The company aims to establish a production base that meets international standards required for developing novel biopharmaceuticals and entering overseas markets.


Hanlim Pharmaceutical, the parent company of HL Genomics, is a leading local pharmaceutical company with roots in Yongin. In June 2026, Hanlim Pharmaceutical also began construction of an urban high-tech industrial complex in the Yurim-dong area to expand production of prescription medicines for export, with the goal of obtaining U.S. Food and Drug Administration (FDA) approval under current Good Manufacturing Practice (cGMP) standards. With both the parent company and its subsidiary making large-scale facility investments in succession, the strengthening of Yongin's biotech supply chain is expected to gain momentum.



Yongin Mayor Lee Sangil said, "As this industrial complex will host companies with actual demand in the advanced biotechnology sector, we will actively support the project to ensure the facilities are built without disruption. We will do our utmost to make Yongin a business-friendly city where companies can grow steadily."


This content was produced with the assistance of AI translation services.

© The Asia Business Daily. All rights reserved. Unauthorized AI training and use prohibited.

Today’s Briefing